Guardian Pharmacy Services, Inc. Class A (GRDN)

In Q3 2025, Guardian Pharmacy Services reported EPS of $0.25, surpassing estimates, and revenues also exceeded expectations. In January 2026, the company reaffirmed its 2025 revenue guidance of $1.43 billion to $1.45 billion and adjusted EBITDA guidance of $104 million to $106 million, while also projecting 2026 revenue between $1.40 billion and $1.42 billion. Analysts have maintained a "Moderate Buy" consensus rating for GRDN, with Oppenheimer raising its price target to $35. The stock has shown momentum, with a 90-day share price return of 29.03% and a 1-year total shareholder return of 49.83% as of January 13, 2026. Institutional investors hold a significant portion of the company's shares, with reports in January 2026 highlighting 35% institutional ownership and the top five shareholders controlling approximately 52% of the company.

Demand for pharmacy services can exhibit seasonality, with increased demand during colder months due to the flu season and other respiratory infections. Spring and summer may bring increased demand for allergy medications and sunscreens. For Guardian Pharmacy Services, the underlying business is supported by rising senior populations and industry consolidation, suggesting a more stable, long-term demand trend, though general health trends would still apply to the residents they serve.

Guardian Pharmacy Services is a pharmacy services company providing technology-enabled medication management solutions to residents of long-term health care facilities (LTCFs) across the United States. The company specializes in offering individualized clinical, drug dispensing, and administration capabilities tailored for residents in lower acuity LTCFs. Their services aim to help residents adhere to appropriate drug regimens, reduce care costs, and improve clinical outcomes. Key offerings include the Guardian Compass platform, GuardianShield Programs for LTCFs, an Order Entry QA Analyzer, and a Medication Spend Analyzer.

Guardian Pharmacy Services operates a national network of over 50 locally-managed pharmacies. As of September 30, 2025, the company served approximately 204,000 residents in nearly 6,800 facilities across 37 states, deriving all revenues in the United States. Recent expansions include the acquisition of Managed Healthcare Pharmacy in Oregon in August 2025, establishing a presence in the state and expanding its Pacific Northwest footprint, and a year-end acquisition of a pharmacy in Montana, extending its geographic reach into a new territory.

Guardian Pharmacy Services has maintained a generally positive brand reputation over the past year. The company has a news sentiment score of 0.88, which is higher than the average for medical companies. Analyst sentiment is moderately positive, with a consensus rating of "Moderate Buy". Recent news has highlighted the company's growth potential, strategic acquisitions, and strong fundamentals, and there have been no significant negative events reported.

Guardian Pharmacy Services has a diverse ownership structure, with institutional investors holding 27.09% to 35% of the stock, insiders owning between 5.46% and 43.69%, and retail investors holding around 18% to 29.21%. Major institutional owners include Brown Advisory Inc., BlackRock, Inc., and Wellington Management Group Llp. Key individual and insider owners include Thomas J. Salentine Jr., William E. Bindley, and Fred Burke.